Early obesity and age-related mimicry of metabolic syndrome in female mice with sex hormonal imbalances

Obesity

Volumn 14, Issue 7, 2006, Pages 1142-1154

  Sairam, M Ram ^a   Wang, Min ^a   Danilovich, Natalia ^a   Javeshghani, Danesh ^a   Maysinger, Dusica ^b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Aging; Follitropin receptor knockout; Glucose intolerance; Inflammation; Insulin receptor

Indexed keywords

ANIMALIA; MUS;

ADIPONECTIN; FOLLITROPIN; FOLLITROPIN RECEPTOR; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SEX HORMONE; SIGNAL PEPTIDE;

ADIPOSE TISSUE; AGING; ANIMAL; ARTICLE; BLOOD; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE TOLERANCE TEST; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; MOUSE; MOUSE MUTANT; OBESITY; PHYSIOLOGY;

ADIPONECTIN; ADIPOSE TISSUE; AGING; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FOLLICLE STIMULATING HORMONE; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; GONADAL STEROID HORMONES; INFLAMMATION; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; METABOLIC SYNDROME X; MICE; MICE, KNOCKOUT; OBESITY; PPAR GAMMA; RECEPTORS, FSH;

EID: 33846881363     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2006.131     Document Type: Article

References (51)

1. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89:2583-9.
2. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33:283-303.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.
4. Larsson B, Bengtsson C, Björntorp P, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Goteborg, Sweden. Am J Epidemiol. 1992;135:266-73.
5. Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab. 1997;82:414-7.
6. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-36.
7. Orio F Jr, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab. 2004;89:3696-701.
8. Simpson ER, Merrill JC, Hollub AJ, Graham-Lorence S, Mendelson CR. Regulation of estrogen biosynthesis by human adipose cells. Endocr Rev. 1989;10:136-48.
9. Szymczak J, Milewicz A, Thijssen JH, Blankenstein MA, Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. Steroids. 1998;63:319-21.
10. Misso ML, Jang C, Adams J, et al. Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. Menopause. 2005;12:210-5.
11. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833-76.
12. Corrales JJ, Burgo RM, Garca-Berrocal B, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metab Clin Exp. 2004;53:666-72.
13. Dierich A, Sairam MR, Monaco L, et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci U S A. 1998;95:13612-7.
14. Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H, Sairam MR. Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology. 2000;141:4295-308.
15. Danilovich N, Maysinger D, Sairam MR. Perspectives on reproductive senescence and biological aging: studies in genetically altered follitropin receptor knockout (FORKO) mice. Exp Gerontol. 2004;39:1669-78.
16. Javeshghani D, Touyz RM, Sairam MR, Fritsch NM, Schiffrin EL. Attenuated responses to angiotensin II in follitropin receptor knockout mice, a model of menopause-associated hypertension. Hypertension. 2003;42:761-7.
17. Jones MEE, Thorburn AW, Britt KL, et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci USA. 2000;97:12735-40.
18. Takeda K, Toda K, Saibara T. Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency. J Endocrinol. 2003;176:237-46.
19. Heine PA, Taylor JA, Iwamoto G A, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci U S A. 2000;97:12729-34.
20. Danilovich N, Sairam MR. Haploinsufficiency of the follicle-stimulating hormone receptor accelerates oocyte loss inducing early reproductive senescence and biological aging in mice. Biol Reprod. 2002;67:361-9.
21. Krishnamurthy H, Babu PS, Morales CR, Sairam MR. Delay in sexual maturity of the follicle-stimulating hormone receptor knockout male mouse. Biol Reprod. 2001;65:522-31.
22. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004;304:1269-73.
23. Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell. 2002;2:497-503.
24. Egan KM, Lawson JA, Fries S, et al. COX-2 derived prostacyclin confers atheroprotection on female mice. Science. 2004;306:1954-7.
25. Olefsky JM, Reaven GM. Effects of age and obesity on insulin binding to isolated adipocytes. Endocrinology. 1975;96:1486-98.
26. Rosen ED, Spiegelman BM. PPAR gamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001;276:37731-4.
27. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet- induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999;4:597-609.
28. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746-9.
29. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271:10697-703.
30. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
31. Shi H, Tzameli I, Bjorbaek C, Flier JS. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem. 2004;279:34733-40
32. von Eyben FE, Mouritsen E, Holm J, et al. Intra-abdominal obesity and metabolic risk factors: a study of young adults. Int J Obes Relat Metab Disord. 2003;27:941-9.
33. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56.
34. Hewitt KN, Pratis K, Jones ME, Simpson ER. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology. 2004;145:1842-8.
35. Hewitt KN, Boon WC, Murata Y, Jones ME, Simpson ER. The aromatase knockout mouse presents with a sexually dimorphic disruption to cholesterol homeostasis. Endocrinology. 2003;144:3895-903.
36. Sairam MR, Danilovich N, Lussier-Cacan S. The FORKO mouse as a genetic model for exploring estrogen replacement therapy. J Reprod Med. 2002;47:412-8.
37. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 2001;507:142-6.
38. Vasseur F, Helbecque N, Dina C, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet. 2002;11:2607-14.
39. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPAR gamma) deficiency and PPAR gamma agonist improve insulin resistance. J Biol Chem. 2001;276:41245-54.
40. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-6.
41. Misso ML, Murata Y, Boon WC, Jones ME, Britt KL, Simpson ER. Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse. Endocrinology. 2003;144:1474-80.
42. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998;101:1354-61.
43. Bluher M, Michael MD, Peroni OD, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell. 2002;3:25-38.
44. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152-62.
45. Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073-80.
46. Kim S, Moustaid-Moussa N. Secretory, endocrine and autocrine/paracrine function of the adipocyte. J Nutr. 2000;130:3110-5S.
47. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S53-5.
48. Bjorbaek C, El Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem. 1999;274:30059-65.
49. Asante-Appiah E, Kennedy BP. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol Endocrinol Metab. 2003;284:E663-70.
50. Ramachandran C, Kennedy BP. Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity. Curr Top Med Chem. 2003;3:749-57.
51. Jones MEE, Thorburn AW, Britt KL, et al. Aromatase-deficient (ArKO) mice accumulate excess adipose tissue. J Steroid Biochem Mol Biol. 2001;79:3-9.